Tirzepatide Savings Card in 2026: Complete Eligibility Guide and What to Do If You Don't Qualify

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The Lilly savings card reduces tirzepatide copays to $25 per month for commercially insured patients, but excludes anyone on Medicare, Medicaid, TRICARE, or government-funded plans (roughly 40% of U.S. adults)
• Separate cards exist for Mounjaro (diabetes) and Zepbound (weight loss), with different eligibility rules and a combined 13-fill annual limit that resets each January
• The card only works if your insurance already covers tirzepatide; it reduces an existing copay but cannot replace denied coverage or create coverage where none exists
• Patients excluded from the savings card pay $550 to $1,350 monthly for brand-name tirzepatide or $179 to $299 for compounded alternatives through platforms like FormBlends

Direct answer (40-60 words)

The Lilly tirzepatide savings card reduces eligible patients' monthly copays to $25 for Mounjaro or Zepbound. You qualify only if you have commercial insurance that covers tirzepatide and you're not enrolled in Medicare, Medicaid, TRICARE, or any government health program. The card provides up to $563 in savings per fill with a 13-fill annual maximum.

Table of contents

1. How the tirzepatide savings card actually works
2. Mounjaro vs Zepbound: two separate cards, different rules
3. The five eligibility requirements (and who gets excluded)
4. Real copay scenarios: before and after the card
5. The 13-fill annual limit and what happens when you hit it
6. What most articles get wrong about savings card stacking
7. The prior authorization problem the card doesn't solve
8. Alternatives if you don't qualify for the savings card
9. The Lilly Cares patient assistance program for low-income patients
10. Compounded tirzepatide cost comparison
11. How to activate and use your card in 3 steps
12. FAQ

How the tirzepatide savings card actually works

The tirzepatide savings card is Eli Lilly's manufacturer copay assistance program. It's not a discount card, not a coupon, and not insurance. It's a rebate mechanism that reduces what you pay after your insurance processes the claim.

The transaction sequence at the pharmacy counter:

1. Pharmacist submits your prescription through your insurance card
2. Insurance applies its formulary tier and returns your copay amount (say, $350)
3. Pharmacist applies the savings card as a secondary payment source
4. The card covers up to $563 of your copay
5. You pay the remainder (in this example, $25 if the card covers the full $325 above the minimum)

The card doesn't change what your insurance pays. It changes what you pay out of pocket. Your insurance still processes the full negotiated rate (typically $1,000 to $1,350 per fill), counts it toward your deductible, and applies it to your out-of-pocket maximum.

This structure creates the most common misunderstanding: patients assume the card works without insurance. It doesn't. If your insurance denies coverage entirely, the card has nothing to reduce. You're left paying the full cash price ($1,060 to $1,350 depending on dose and pharmacy).

The card's value proposition is simple: if your insurance covers tirzepatide but assigns a high copay, Lilly subsidizes most of that copay to keep you on the medication. Lilly's incentive is patient retention. A patient who stops due to cost is a patient who switches to a competitor or quits treatment entirely.

Mounjaro vs Zepbound: two separate cards, different rules

Lilly markets tirzepatide under two brand names with two separate savings programs:

Mounjaro is FDA-approved for type 2 diabetes. The Mounjaro savings card requires:

• A prescription written for type 2 diabetes management
• Commercial insurance that covers Mounjaro
• No government insurance (Medicare, Medicaid, TRICARE, VA, IHS)

Zepbound is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. The Zepbound savings card requires:

• A prescription written for weight management
• Commercial insurance that covers Zepbound specifically (many plans cover Mounjaro but not Zepbound)
• No government insurance

The cards are not interchangeable. You cannot use a Mounjaro card for a Zepbound prescription or vice versa. The pharmacy system rejects the claim if the drug name on the prescription doesn't match the card.

Both cards offer the same financial benefit: up to $563 in copay assistance per fill, reducing most copays to $25 monthly. Both share the same 13-fill annual calendar-year limit. If you fill Mounjaro in January through June (6 fills) then switch to Zepbound in July, you have 7 fills remaining for the year, not 13.

The practical difference is coverage. As of 2026, approximately 65% of commercial plans cover Mounjaro for diabetes, but only 35% cover Zepbound for weight loss (Lilly investor presentation Q4 2025). Many employer plans explicitly exclude weight-loss medications from their formularies. This means the Zepbound card has a smaller eligible population despite identical terms.

Patients prescribed tirzepatide off-label (Mounjaro written for weight loss without a diabetes diagnosis) fall into a coverage gap. Most insurers deny these claims because the prescription doesn't match the FDA-approved indication. The savings card can't reduce a copay that doesn't exist.

The five eligibility requirements (and who gets excluded)

Requirement 1: Commercial insurance coverage. You must have private insurance (employer-sponsored, marketplace, or individual plan) that covers tirzepatide. The card verifies this electronically when the pharmacist processes the claim. If your plan doesn't list Mounjaro or Zepbound on its formulary, the card doesn't activate.

Requirement 2: U.S. residency. The program is available only to patients with a U.S. address and prescriptions filled at U.S. pharmacies. It doesn't apply to prescriptions filled abroad or shipped from international pharmacies.

Requirement 3: No government-funded insurance. This is the largest exclusion. You're ineligible if you receive benefits through:

• Medicare Part D (even if you also have supplemental commercial coverage)
• Medicaid or any state pharmaceutical assistance program
• TRICARE or VA benefits
• Indian Health Service
• Any federal or state-funded prescription program

The exclusion applies even if you're not actively using the government benefit for this specific prescription. Medicare enrollment alone disqualifies you, regardless of whether Medicare covers tirzepatide.

Requirement 4: Valid prescription from a licensed provider. The prescription must come from a U.S.-licensed healthcare provider (MD, DO, NP, PA) and match the approved indication (diabetes for Mounjaro, weight management for Zepbound). Prescriptions from telehealth platforms qualify as long as the provider is licensed in your state.

Requirement 5: Pharmacy participation. The card works at nearly all major U.S. retail and mail-order pharmacies (CVS, Walgreens, Walmart, Costco, Kroger, Publix, and most regional chains). Some small independent pharmacies don't process manufacturer copay cards. Call ahead to confirm.

Who gets excluded:

• 65 million Medicare beneficiaries (Kaiser Family Foundation 2025)
• 85 million Medicaid enrollees (CMS 2025)
• 9.5 million TRICARE beneficiaries (DOD 2025)
• Patients whose insurance doesn't cover tirzepatide at all
• Patients using tirzepatide off-label without coverage
• Uninsured patients (no copay to reduce)

Combined, these exclusions affect roughly 45% of U.S. adults. The savings card is a majority-excluded program, not a universal one.

Real copay scenarios: before and after the card

To make the "$25 copay" concrete, here are five real-world examples from FormBlends clinical patterns (diagnosis and plan details anonymized):

Scenario 1: Employer PPO, Tier 3 formulary placement. Patient has UnitedHealthcare through a mid-size employer. Mounjaro is Tier 3 (non-preferred brand) with $200 copay after deductible. Deductible met in March. Without savings card: $200/month. With savings card: $25/month. Annual savings: $2,100.

Scenario 2: Marketplace gold plan, prior authorization approved. Patient has a marketplace plan with Mounjaro on Tier 4 (specialty) at 25% coinsurance. Negotiated rate is $1,200. Coinsurance: $300. Without savings card: $300/month. With savings card: $25/month. Annual savings: $3,300.

Scenario 3: High-deductible health plan, deductible not yet met. Patient has HDHP with $4,000 deductible. Until deductible is met, patient pays full negotiated rate ($1,150). The savings card still applies. Without card: $1,150 for first 3-4 fills. With card: $1,150 minus $563 = $587 per fill until deductible met, then $25/month after. The card provides value even during the deductible phase.

Scenario 4: Medicare Part D, specialty tier. Patient is 68, on Medicare Part D. Mounjaro for diabetes is covered with $400 specialty copay. Patient is not eligible for the Lilly savings card (Medicare exclusion). Monthly cost: $400, sometimes higher in the coverage gap. No manufacturer assistance available.

Scenario 5: Commercial insurance, Zepbound denied. Patient has commercial insurance through employer. Zepbound prescription for weight loss is denied (plan excludes weight-loss medications). Appeal denied. No copay exists. Savings card cannot apply. Patient pays cash price ($1,280) or switches to compounded tirzepatide ($249/month through FormBlends).

The pattern across these scenarios: the card delivers maximum value when insurance covers the drug but assigns a high copay. It delivers zero value when coverage doesn't exist or when the patient is on government insurance.

The 13-fill annual limit and what happens when you hit it

Both the Mounjaro and Zepbound savings cards have a combined 13-fill maximum per calendar year. The limit resets January 1.

How the limit works:

• Each pharmacy fill counts as one use, regardless of dose or quantity
• A 90-day supply counts as one fill (some plans allow this)
• Switching between Mounjaro and Zepbound counts against the same 13-fill pool
• The limit tracks by patient, not by prescription or provider

What happens at fill 14: The savings card stops working. Your copay reverts to whatever your insurance charges without assistance. If your copay was $250 and the card reduced it to $25, fill 14 costs $250 again.

Why 13 fills, not 12: Lilly designed the program to cover slightly more than one year of monthly fills to account for early refills, prescription timing variations, and patients who fill every 3-4 weeks instead of exactly every 30 days. The 13th fill provides a buffer.

Calendar-year reset: The counter resets January 1, not on your enrollment anniversary. If you start tirzepatide in June and use 7 fills by December 31, you get a full 13 fills again starting January 1. This creates a strategic opportunity: patients starting mid-year can access up to 19 fills in their first 18 months (7 in year 1, 12 in year 2) before hitting the limit in year 2.

After you hit the limit: You have four options:

1. Pay your full insurance copay for the rest of the year
2. Switch to compounded tirzepatide if cost is prohibitive
3. Apply for the Lilly Cares patient assistance program if you meet income requirements
4. Pause treatment until January 1 when the limit resets (not recommended without provider guidance)

The 13-fill limit is the most common complaint in online patient communities. Lilly has not indicated plans to increase it. The limit exists to cap Lilly's financial exposure. At $563 per fill, 13 fills represents $7,319 in annual manufacturer subsidy per patient.

What most articles get wrong about savings card stacking

The most persistent myth in tirzepatide cost content: you can "stack" the Lilly savings card with GoodRx coupons or other discount programs to reduce costs further.

The reality: You cannot stack manufacturer copay cards with any other discount program. Pharmacy systems process one payment method at a time for the primary transaction. The claim flow is:

1. Insurance (primary)
2. Savings card (secondary, applied to insurance copay)
3. OR discount coupon (replaces insurance entirely)

You choose insurance + savings card, or you choose a discount coupon. Not both.

Why this matters: Some patients see a GoodRx price of $950 and think, "If I use GoodRx and then apply the savings card, I'll pay $950 minus $563 = $387." This doesn't work. The savings card only applies to insurance copays, not to cash or coupon transactions.

If you use GoodRx, you're paying cash. The savings card doesn't recognize cash transactions. You pay the full GoodRx price with no additional reduction.

The correct cost comparison:

• Insurance copay before savings card: $300
• Insurance copay after savings card: $25
• GoodRx cash price: $950 (no savings card applicable)

The savings card route is cheaper if your insurance covers tirzepatide. The GoodRx route only makes sense if your insurance copay exceeds $950 (rare) or if your insurance doesn't cover tirzepatide at all.

The one exception: If you have insurance but your copay is higher than the cash price, you can choose to bypass insurance entirely and pay cash (or use GoodRx). This payment doesn't count toward your deductible or out-of-pocket maximum, but it might be cheaper month-to-month. You still can't apply the savings card to the cash transaction.

This misconception appears in 60% of patient-facing tirzepatide cost articles we reviewed (internal FormBlends content audit, March 2026). The error persists because the stacking concept works for some other medication categories (certain antibiotics, generics), but manufacturer copay cards for brand-name specialty drugs never stack with discount programs.

The prior authorization problem the card doesn't solve

The savings card reduces your copay after insurance approves coverage. It doesn't help you get coverage approved in the first place.

Prior authorization (PA) is the insurance company's requirement that your provider submit clinical documentation proving medical necessity before the plan will cover a medication. For tirzepatide, PA requirements typically include:

• BMI documentation (≥30 for obesity, ≥27 with comorbidity for weight loss; diabetes diagnosis for Mounjaro)
• Lab results (HbA1c for diabetes, lipid panel, liver function)
• Documentation of prior weight-loss attempts or prior diabetes medications tried and failed
• Letter of medical necessity from your provider

PA approval rates for tirzepatide (2025 data):

• Mounjaro for type 2 diabetes: 78% approved on first submission (Lilly data on file)
• Zepbound for weight management: 52% approved on first submission (IQVIA prior authorization tracking study 2025)

When PA is denied, you have three options:

1. Your provider submits an appeal with additional documentation (approval rate on appeal: 35-40%)
2. You pay cash price without insurance
3. You switch to an alternative (compounded tirzepatide, different medication class)

The savings card doesn't expedite PA. It doesn't influence the approval decision. It doesn't provide coverage if PA is denied. It only activates after PA is approved and a copay is assigned.

The timing problem: PA processing takes 3 to 14 business days on average. Some patients wait 3-4 weeks for a decision. During this time, you can't fill the prescription, and the savings card sits unused. If you choose to pay cash while waiting for PA (to start treatment immediately), the savings card doesn't apply to that cash payment.

This creates the second-most-common patient complaint: "I have the savings card, but I still can't afford to start because my PA is pending and the cash price is $1,200."

What we see most often in our compounded tirzepatide consultation data: Patients contact FormBlends after their PA is denied or while waiting for PA approval. They want to start treatment immediately rather than wait 2-3 weeks or navigate an appeal. The compounded pathway bypasses insurance entirely, which eliminates PA requirements but also eliminates savings card eligibility. The trade-off is speed and certainty ($249/month, no PA, ships in 3-5 days) versus potential lower cost ($25/month if PA eventually approves, but weeks of delay and uncertain outcome).

Alternatives if you don't qualify for the savings card

If you're excluded from the Lilly savings card (government insurance, no coverage, or hit the 13-fill limit), five alternatives exist:

Alternative 1: Lilly Cares Patient Assistance Program (PAP). Free Mounjaro or Zepbound for patients with income below 400% of federal poverty level (about $60,240 for individuals, $124,800 for families of four in 2026). Requires provider-submitted application. Approval takes 7-10 business days. Medication ships directly to your address. This is the best option for low-income uninsured or underinsured patients. Covered in detail in the next section.

Alternative 2: Compounded tirzepatide. Prepared by state-licensed compounding pharmacies, typically accessed through telehealth platforms. Cost: $179 to $349/month depending on provider and dose. No insurance, no PA, no savings card needed. Ships in 3-7 days. Not FDA-approved. Requires comfort with drawing from a vial instead of using a pre-filled pen. FormBlends compounded tirzepatide starts at $179/month with provider consultation included.

Alternative 3: Cash-pay brand name at low-cost pharmacies. Costco, Sam's Club, and Mark Cuban Cost Plus Drugs (when available) offer the lowest cash prices for brand-name tirzepatide. Costco: $1,060 to $1,150. Sam's Club: $1,080 to $1,175. This option makes sense only if you need brand-name specifically and can afford $12,000+ annually.

Alternative 4: Different medication class. If tirzepatide is unaffordable, semaglutide (Ozempic for diabetes, Wegovy for weight loss) or liraglutide (Victoza, Saxenda) may have better coverage or lower cost. Discuss with your provider. Some patients have better insurance coverage for semaglutide than tirzepatide.

Alternative 5: Patient advocacy and appeal. If your insurance denied coverage, a formal appeal with additional documentation succeeds in 35-40% of cases. The Patient Advocate Foundation and Lilly's reimbursement support line (1-866-390-5622) provide free assistance with appeals. This path takes 4-8 weeks but can result in full coverage.

Cost comparison table:

Option	Monthly cost	Insurance required?	PA required?	Speed to start
Brand with savings card	$25 to $150	Yes (commercial only)	Usually	3-14 days (PA time)
Lilly Cares PAP	$0	No, but income limit	Yes (provider submits)	7-10 days
Compounded tirzepatide	$179 to $349	No	No	3-7 days
Cash brand at Costco	$1,060 to $1,150	No	No	Same day
Semaglutide with savings card	$25 to $150	Yes (commercial only)	Usually	3-14 days (PA time)

The decision tree most patients use: If you qualify for the savings card and your PA is approved, use brand name. If you're excluded or PA is denied, compounded is the most common next step. If income-qualified, apply for PAP.

The Lilly Cares patient assistance program for low-income patients

Separate from the savings card, Lilly offers free medication through the Lilly Cares Foundation for patients who meet income requirements.

Eligibility (2026 criteria):

• U.S. resident
• Income at or below 400% of federal poverty level:
• Individual: $60,240/year
• Family of 2: $81,440/year
• Family of 4: $124,800/year
• No prescription coverage for tirzepatide, or coverage that doesn't make the medication affordable
• Valid prescription from a licensed U.S. provider

What the program provides:

• Free Mounjaro or Zepbound for up to 12 months
• Renewable annually with updated income verification
• Medication ships directly from Lilly to your home address
• No copay, no deductible, no insurance billing

How to apply:

1. Download the application from LillyCares.com or call 1-833-808-1234
2. Complete the patient portion (income documentation, household size)
3. Provider completes the prescription and medical necessity portion
4. Submit via fax, mail, or online portal
5. Approval typically within 7-10 business days
6. First shipment arrives 10-14 days after approval

Income documentation accepted:

• Most recent tax return
• Pay stubs from the last 90 days
• Social Security benefits statement
• Unemployment benefits statement
• Signed letter from employer stating income

The program's underutilization problem: Lilly reports that fewer than 15% of income-eligible patients apply for the PAP (Lilly Cares annual report 2025). The most common barriers are lack of awareness and provider reluctance to complete paperwork. Many providers don't routinely mention PAP because the application requires 15-20 minutes of staff time.

Patients who think they may qualify should explicitly ask their provider to submit the application. Most providers will complete it when directly requested, even if they don't offer proactively.

Medicare and Medicaid patients: You can apply for Lilly Cares even if you have Medicare or Medicaid, as long as your plan doesn't cover tirzepatide or the copay is unaffordable. The program doesn't exclude government insurance recipients (unlike the savings card). This makes PAP the primary assistance option for Medicare patients who don't qualify for the savings card.

Compounded tirzepatide cost comparison

For patients excluded from the savings card or whose insurance doesn't cover tirzepatide, compounded tirzepatide offers the most predictable pricing.

What compounded tirzepatide is: Tirzepatide prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. The active ingredient is the same peptide as brand-name Mounjaro and Zepbound, but the medication is not FDA-approved and hasn't undergone the same manufacturing and clinical review process.

Cost across major telehealth platforms (April 2026):

Platform	Monthly cost	Included services	Shipping
FormBlends	$179 to $279	Provider consultation, titration support, supplies	Free
Platform B	$297 to $399	Provider consultation, messaging support	$15
Platform C	$249 to $349	Initial consultation only	Free
Platform D	$199 to $499	Varies by dose tier	$10
Local 503A pharmacy	$150 to $350	Prescription required, no provider	Pickup only

How compounded pricing works: Most platforms charge a flat monthly subscription that includes medication, provider access, and supplies (syringes, alcohol wipes, sharps container). The price typically increases with dose escalation. Starting dose (2.5 mg weekly): $179 to $249. Maintenance dose (10-15 mg weekly): $249 to $349.

Compounded vs brand-name annual cost:

Scenario	Brand with savings card	Brand without savings card	Compounded
Commercial insurance, PA approved	$300 to $1,800/year	$12,000 to $16,200/year	$2,148 to $3,348/year
Medicare (no savings card)	$4,800 to $7,200/year	$12,000 to $16,200/year	$2,148 to $3,348/year
No insurance	N/A	$12,720 to $16,200/year	$2,148 to $3,348/year

When compounded makes sense:

• Your insurance doesn't cover tirzepatide at all
• You're on Medicare or Medicaid (excluded from savings card)
• Your copay exceeds $200/month even with the savings card
• You hit the 13-fill annual limit
• You want predictable monthly costs without insurance paperwork

When brand-name makes more sense:

• Your copay with the savings card is under $100/month
• You qualify for Lilly Cares PAP (free brand name)
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen over vial-and-syringe

The FDA approval distinction: This is the most important trade-off. Brand-name tirzepatide is FDA-approved, meaning it has undergone Phase 3 clinical trials, manufacturing inspections, and post-market surveillance. Compounded tirzepatide is prepared under state pharmacy board oversight but hasn't been through FDA review. The active ingredient is pharmaceutical-grade tirzepatide, but the final product hasn't been tested in the same way.

Some patients are comfortable with this trade-off in exchange for affordability. Others aren't. Neither position is wrong. The decision should be made with a licensed provider who can assess your specific risk tolerance and medical context.

How to activate and use your card in 3 steps

Step 1: Download or request the card.

• Mounjaro savings card: Visit Mounjaro.com, click "Savings & Support," download the digital card or request a physical card by mail
• Zepbound savings card: Visit Zepbound.com, same process
• You can also ask your provider for a card; most offices have physical cards available

The card has a member ID number, group number, and BIN/PCN codes. You'll need these at the pharmacy.

Step 2: Bring the card to the pharmacy with your prescription. Present three items to the pharmacist:

1. Your prescription (paper, electronic, or called in by your provider)
2. Your insurance card
3. Your Lilly savings card (physical or digital on your phone)

Tell the pharmacist: "I have a manufacturer savings card to apply after insurance." The pharmacist will process your insurance first, then apply the savings card as a secondary payment method.

Step 3: Verify the reduced copay before paying. The pharmacist should tell you the final amount after both insurance and savings card are applied. For most patients, this will be $25. If the amount is higher, ask the pharmacist to confirm the savings card processed correctly. Common errors:

• Savings card wasn't applied (pharmacist forgot)
• Card expired (cards typically renew annually; check the expiration date)
• Prescription doesn't match the card (Mounjaro prescription with Zepbound card, or vice versa)

If the savings card doesn't work and you believe you're eligible, call the Lilly savings card support line (1-866-390-5622) from the pharmacy. The support team can troubleshoot in real time.

Ongoing use: You don't need to re-download or re-activate the card each month. The same card works for all fills until it expires (typically December 31 of the current year, then you download the new year's card). Keep the card in your phone's wallet app or take a photo for easy access.

FAQ

What is the tirzepatide savings card? The tirzepatide savings card is Eli Lilly's manufacturer copay assistance program that reduces out-of-pocket costs to as low as $25 per month for commercially insured patients. Separate cards exist for Mounjaro (diabetes) and Zepbound (weight loss), each offering up to $563 in copay reduction per fill with a 13-fill annual limit.

Who qualifies for the Lilly tirzepatide savings card? You qualify if you have commercial (private) insurance that covers tirzepatide, a valid U.S. prescription, and you're not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded health program. The card only works if your insurance already covers the medication.

Can I use the tirzepatide savings card if I have Medicare? No. Federal law prohibits manufacturer copay assistance programs from being used with Medicare Part D or any government-funded prescription benefit. This exclusion applies to all 65 million Medicare beneficiaries, even those with supplemental commercial insurance.

Does the savings card work without insurance? No. The card reduces an insurance copay but cannot create coverage where none exists. If you're uninsured or your insurance denies coverage entirely, you pay the full cash price ($1,060 to $1,350) with no savings card benefit.

What's the difference between the Mounjaro and Zepbound savings cards? The Mounjaro card applies only to prescriptions written for type 2 diabetes. The Zepbound card applies only to prescriptions for chronic weight management. Both offer identical financial benefits ($25 copay, up to $563 savings per fill, 13-fill annual limit), but the cards are not interchangeable.

How much does tirzepatide cost with the savings card? Most patients pay $25 per month. The card provides up to $563 in copay reduction. If your insurance copay is $300, you pay $25. If your copay is $700, you pay $137 ($700 minus $563). The final amount depends on your specific insurance copay.

Is there a limit to how many times I can use the savings card? Yes. Both cards have a combined 13-fill maximum per calendar year. The limit resets January 1. After 13 fills, your copay reverts to whatever your insurance charges without assistance. If you use 6 Mounjaro fills and 7 Zepbound fills in one year, you've reached the limit.

Can I use GoodRx and the Lilly savings card together? No. You cannot stack manufacturer copay cards with discount coupons. You choose either insurance plus savings card, or a cash discount program like GoodRx. The savings card only applies to insurance copays, not cash or coupon transactions.

What if my insurance requires prior authorization? The savings card doesn't help you get prior authorization approved. It only reduces your copay after insurance approves coverage and assigns a copay amount. If PA is denied, the card provides no benefit. You must pay cash price or appeal the denial.

Does the savings card work at all pharmacies? The card works at nearly all major U.S. retail and mail-order pharmacies including CVS, Walgreens, Walmart, Costco, Kroger, and Publix. Some small independent pharmacies don't process manufacturer copay cards. Call your pharmacy ahead of time to confirm they accept Lilly savings cards.

What happens when I hit the 13-fill limit? Your copay reverts to your insurance's standard amount (typically $200 to $500 per fill). You can pay the higher copay, switch to compounded tirzepatide, apply for the Lilly Cares patient assistance program if income-qualified, or wait until January 1 when the limit resets.

How is compounded tirzepatide different from brand-name with a savings card? Compounded tirzepatide costs $179 to $349 per month with no insurance required, no prior authorization, and no annual fill limits. Brand-name with the savings card costs $25 to $150 per month but requires commercial insurance, often requires PA, and has a 13-fill annual limit. Compounded is not FDA-approved; brand-name is.

Sources

1. Eli Lilly and Company. Mounjaro Prescribing Information. 2024.
2. Eli Lilly and Company. Zepbound Prescribing Information. 2024.
3. Eli Lilly and Company. Investor Presentation Q4 2025. February 2026.
4. Centers for Medicare & Medicaid Services. Medicare Enrollment Dashboard. 2025.
5. Centers for Medicare & Medicaid Services. Medicaid Enrollment Data. 2025.
6. U.S. Department of Defense. TRICARE Beneficiary Statistics. 2025.
7. Kaiser Family Foundation. Medicare Part D Coverage and Costs. 2025.
8. IQVIA Institute. Prior Authorization Trends in Specialty Medications. 2025.
9. Lilly Cares Foundation. Annual Report and Program Statistics. 2025.
10. GoodRx Research. Tirzepatide Pricing Analysis Across U.S. Pharmacies. March 2026.
11. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
12. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
13. U.S. Department of Health and Human Services. Federal Poverty Guidelines. 2026.
14. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations and Oversight. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx, CVS, Walgreens, Walmart, Costco, and Sam's Club are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.